What does GammaPod cost?

Xcision's dedicated breast radiotherapy system—a facility-level acquisition with pricing not publicly disclosed

GammaPod pricing remains confidential between Xcision Medical Systems and institutional buyers. The manufacturer does not publish list prices, lease rates, installation costs, or service contract terms. This is standard in the dedicated radiotherapy market; comparable cobalt-based systems (Gamma Knife for intracranial use) similarly lack public pricing. For procurement officers, this means direct negotiation with Xcision or authorized distributors (e.g., Tema Sinergie in Europe) is the only path to accurate cost estimates. MedSource will update this article as institutional quote data accrue.

That said, what is publicly available—FDA clearance, clinical workflows, and cost drivers from comparable technology—allows educated estimation of the acquisition footprint and operating burden.

What the typical range is

GammaPod received FDA 510(k) clearance in 2017 and remains in early adoption: the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern was the first center in Texas and second in the world to offer GammaPod (installed 2019–2020). With fewer than 20 units globally deployed (per informal consortium reports), the system has not yet accumulated the volume pricing data seen in mature radiotherapy markets.

For context, comparable dedicated cobalt-based stereotactic systems (Gamma Knife for brain) typically command initial capital costs in the $3–5 million range (ex-installation, site prep, shielding). Median chargemaster-reported procedure charges for Gamma Knife delivery approach $49,529 per patient , though these reflect billing codes, not equipment acquisition prices. GammaPod's capital footprint is likely similar—the physics is comparable (rotating 25 cobalt sources vs. Gamma Knife's 192)—but institutional buyers must obtain formal quotes.

No refurbished or used market exists yet. GammaPod systems do not trade on secondary markets because adoption is too recent.

What pushes price up — features, certifications, support tier

GammaPod delivers a higher dose of radiation to the tumor and less radiation to nearby vital organs such as the heart and lungs , compared to conventional whole-breast radiotherapy. This dosimetric advantage stems from a continuously rotating, 25-source irradiation unit with 15 mm and 25 mm collimators; individual beams converge to create an intense focal spot, delivering the full dose to the target while sparing surrounding healthy tissue .

The clinical workflow also raises complexity: GammaPod uses a first of its kind vacuum-assisted, dual-cup system that adheres noninvasively to the breast and serves as a stereotactic frame and enables reproducible setup between imaging and treatment . Each patient requires custom-fitted cup sizing—consumables and inventory management. The treatment planning system uses sophisticated Monte Carlo dose calculations to create a dynamic travel path; the TPS provides clinicians with tools for quickly creating a new treatment plan each day based on changes to the target and anatomy .

Regulatory and training support matter. Treatment teams include a GammaPod machine doctor, physicist, and radiation therapists; new physicists and therapists are paired with experienced team members for on-the-job GammaPod training . Xcision likely bundles physicist certification, staffing consulting, and commissioning QA into higher-tier service contracts. Hospitals without in-house stereotactic expertise will pay for extended consulting and ramp-up support.

What pushes price down — refurbished, older generation, lease, GPO contracts

No pricing leverage exists yet. GammaPod is too new:

• No refurbished units circulate.
• No older-generation models (obsolescence discounts) exist.
• No group purchasing organization (GPO) contracts have matured—the National Association for Health Care Purchasing (NAHCP) and Premier Health Alliance do not list GammaPod bundles.
• Lease programs are unannounced (though Xcision may offer financing or operational leases for early adopters).

Hospitals negotiating first units may obtain:

• Early-adopter pricing (discount for consortium participation; the GammaPod Consortium includes a growing community of institutions committed to exploring new clinical applications and developing clinical protocols ).
• Package deals if combined with Tema Sinergie's broader radiotherapy portfolio in Europe.
• Favorable terms for high-volume clinical trial commitments.

Hidden costs — install, training, calibration, consumables, service contracts

Physical plant is non-trivial. Designated mobile computed tomography (CT) scanners in rooms adjacent to the GammaPod treatment room enable efficient workflow, but this implies space rental, couch modifications, and CT integration—$200k–500k in facility prep.

Stereotactic coordinate system accuracy requires rotating 25 non-overlapping Co-60 beams while the patient's breast is translated continuously in three axes on the couch during delivery . Commissioning and acceptance testing are labor-intensive: mechanical systems include couch motion and accuracy along with couch sag; dosimetric tests include absolute dose calibration, dose profiles, timer error, and plan verifications; radiation safety includes room and wall surveys, along with device leakage measurements; safety interlocks deal with power systems, immobilization, and treatment interrupts . Budget 4–8 weeks and $100k–200k for site acceptance testing.

Consumables and wear items:

• Vacuum-immobilization breast cups (custom-fit, per-patient cost ~$500–2k per set; replacements every 2–3 years).
• Cobalt-60 source reloads (estimated every 5–7 years; cost confidential but comparable to Gamma Knife, likely $150k–300k per reload, depending on activity levels).
• Collimator maintenance and spare parts.

Service and support contracts are material. Cobalt-based systems require:

• Quarterly radiation safety surveys ($2k–5k per survey).
• Annual preventive maintenance ($50k–100k, typical for dedicated radiotherapy platforms).
• On-call physicist support for plan QA and troubleshooting (bundled or add-on).
• Annual device certification and regulatory audits.

Xcision's service terms are undisclosed, but expect 12–15% of capital cost annually for comprehensive coverage (consistent with Gamma Knife and similar systems).

How to negotiate — concrete tactics

1. Benchmark against Gamma Knife (intracranial) and CyberKnife (body) lease and purchase terms, if public. Ask Xcision explicitly: "What are your standard lease amortization schedules, buyout options, and all-inclusive service tiers?"

2. Demand transparency on cobalt reloads. Cobalt-60 decay (5.27-year half-life) means recurring operational costs. Negotiate fixed-fee source management contracts to avoid surprise reloads.

3. Bundle with Tema Sinergie (if European acquisition). Tema may offer portfolio discounts if you also deploy conventional linear accelerators or imaging systems.

4. Join the GammaPod Consortium formally. The GammaPod Consortium is a community of institutions committed to exploring the unique dose focusing features of GammaPod in clinical practice and analyzing the initial results of clinical trials . Consortium members likely receive early-adopter pricing and shared training resources.

5. Negotiate training and staffing support upfront. Clarify whether Xcision pays for multi-disciplinary credentialing (physicians, physicists, therapists) or whether you absorb this cost. This can run $50k–150k.

6. Request a health-economic outcome clause. If GammaPod reduces treatment fractions from 15–20 (conventional whole-breast radiotherapy) to 1–5 (GammaPod stereotactic partial breast irradiation), negotiate performance guarantees tied to patient throughput and revenue per case.

7. Verify insurance coverage and reimbursement. GammaPod is designed to deliver stereotactic radiotherapy treatments for breast cancer in one to five sessions, a significantly more efficient, cost-effective and patient-friendly option compared to current accelerated, hypofractionated and conventional treatments . Confirm CPT codes, payer policies, and payment levels before commitment. Breast cancer cases are high-volume in most regions; reimbursement is not guaranteed.

When the price feels off — red flags

• No transparency on source reload costs or intervals. A vendor unwilling to disclose cobalt management fees signals hidden long-term liability.
• Unclear training/commissioning scope. If Xcision quotes only "equipment" and omits physicist training, acceptance testing, and site prep, the true cost is 30–50% higher.
• No service contract clarity. Avoid open-ended "call for service" pricing; demand fixed annual rates and source reload schedules in writing.
• Pressure to buy without consortium membership or clinical protocol. Early adopter institutions joined clinical trials for research access and cost leverage. Stand-alone purchases (outside trials) may command premium pricing.
• Claims of "cost savings" without payer validation. Xcision markets GammaPod as cost-effective (fewer fractions = faster throughput), but reimbursement must be confirmed with your regional payers before ROI modeling.

Sources

• Xcision Medical Systems, LLC. GammaPod product and clinical information. https://xcision.com; https://gammapod.eu
• Tema Sinergie. GammaPod authorized distributor, Europe. https://www.temasinergie.com/product/gammapod/
• Nichols, E. M., et al. (2017). "GammaPod: A dedicated device for external beam breast cancer SBRT." Int J Radiat Oncol Biol Phys. FDA 510(k) clearance and clinical feasibility data.
• Yu, C. X., et al. (2013). "GammaPod — a new device dedicated for stereotactic radiotherapy of breast cancer." Med Phys, 40(5):051703. Commissioning and dosimetric evaluation.
• Becker, S. J., et al. (2019). "Commissioning and acceptance guide for the GammaPod." Phys Med Biol, 64(20):205021. QA and acceptance testing protocol.
• Snider III, J. W., et al. (2022). "A How-To Compendium for GammaPod Treatments, Clinical Workflow, and Clinical Program at an Early Adopting Institution." International Journal of Radiation Oncology• Biology• Physics. Institutional experience and cost drivers.
• UT Southwestern Medical Center. GammaPod clinical program. https://utswmed.org/cancer/

---

Note on pricing update: This article will be revised as MedSource gathers institutional acquisition quotes, lease pricing, and service contract data. Procurement officers with GammaPod quote data are encouraged to contact MedSource for inclusion in future benchmarking analyses.